Product Information
LEUPROLIDE 2WK 14 MG/2.8 ML KT is a generic product labeled by Eugia US LLC, priced at $197.6060 per EA under NDC 55150047801. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jun 6, 2022. Its Orange Book therapeutic-equivalence code is AP.
Manufacturer
Eugia US LLCNDC
55150047801
Classification
Generic
Dosage Form
KIT
Effective Date
5/20/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA212963FDA Approved
6/6/2022
TE Code
AP
On Market Since
6/6/2022
Price Statistics
The NADAC for LEUPROLIDE 2WK 14 MG/2.8 ML KT has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 14.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $197.6060 per EA |
|---|---|
| All-time high | $301.8717 (Sep 10, 2025) |
| All-time low | $197.6060 (May 20, 2026) |
| 52-week high | $261.3184 |
| 52-week low | $197.6060 |
| Median price | $256.3443 |
| Average price | $250.9381 |
| Largest weekly change | +23.4% (Aug 21, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LEUPROLIDE ACETATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eugia US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LEUPROLIDE ACETATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEUPROLIDE 2WK 14 MG/2.8 ML KT?
The current National Average Drug Acquisition Cost (NADAC) for LEUPROLIDE 2WK 14 MG/2.8 ML KT, manufactured by Eugia US LLC, is $197.6060 per EA (NDC 55150047801), effective Sep 30, 2026.
How has the price of LEUPROLIDE 2WK 14 MG/2.8 ML KT changed over time?
Over the history we have for it, the NADAC for LEUPROLIDE 2WK 14 MG/2.8 ML KT has declined 14.2%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for LEUPROLIDE 2WK 14 MG/2.8 ML KT?
Since Apr 17, 2024, the NADAC for LEUPROLIDE 2WK 14 MG/2.8 ML KT has ranged from a low of $197.6060 (May 20, 2026) to a high of $301.8717 (Sep 10, 2025), with a median of $256.3443 per EA.
Are there cheaper alternatives to LEUPROLIDE 2WK 14 MG/2.8 ML KT?
No other NADAC-published product currently shares the active ingredient and strength of LEUPROLIDE 2WK 14 MG/2.8 ML KT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LEUPROLIDE 2WK 14 MG/2.8 ML KT?
LEUPROLIDE 2WK 14 MG/2.8 ML KT (NDC 55150047801) is labeled by Eugia US LLC, and CMS classifies it as a generic product.